ADX71149 for epilepsy

ADX71149 (mGlu2 PAM) for the treatment of epilepsy.

Our partnered drug candidate, ADX71149 is a novel orally active metabotropic glutamate receptor subtype 2, or mGlu2 PAM.

Our partner, Janssen, has completed Phase 1 and two Phase 2a clinical trials in schizophrenia and anxious depression, respectively, and is currently evaluating future development in epilepsy.

Under our agreement with Janssen, Janssen is responsible for financing the development and commercialization, if any, of ADX71149.